Swedish inhaled product developer Iconovo has announced a deal with Japanese pharmaceutical company TOA for development of Iconovo’s ICOone unit dose dry powder inhaler for the treatment of asthma and COPD. TOA’s Nishihongo facility includes a building dedicated to DPI manufacturing and filling that has been in operation since 2007.
According to Iconovo, the companies signed a letter of intent in December 2017 for development of one of Iconovo’s three DPI platforms for the Japanese market; the current announcement reflects a focus on the ICOone platform specifically. Iconovo also offers reservoir-based and capsule-based DPI platforms.
Iconovo CEO Orest Lastow said, “This is an important milestone for Iconovo. Together with TOA we are aiming at entering the dynamic Japanese market for asthma and COPD treatment. We are thrilled to evaluate these opportunities together with TOA.”
